The European Commission approved a two-dose schedule for Gardasil 9, for adolescent girls and boys aged 9 to 14, in the 31 countries regulated by the European Medicines Agency.
The University of Chicago and Evelo Biosciences entered into a license agreement to develop and commercialize a microbiome-based cancer immunotherapy. The cancer therapy, developed in the laboratories of UChicago researcher Thomas Gajewski, employs select gut microbes to boost the immune system’s attack on cancer cells and improve the efficacy of anti-cancer drugs. “This is the... […]
Sysmex Inostics, a subsidiary of Sysmex Corp., announced that its OncoBEAM RAS CRC test was granted CE mark approval. The CE mark is a mandatory conformity marking for certain products sold within the European Economic Area. The test, developed by Sysmex Inostics GmbH in collaboration with Merck, can now be accessed by patients with metastatic... […]
Halaven (eribulin) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, to extend Halaven’s license to include patients with unresectable liposarcomas who have received prior anthracycline containing therapy for advanced or metastatic disease. The opinion is based on phase III data demonstrating a median 7.2 month increase in... […]
SCHULMAN IRB was selected as the national IRB for the Cancer MoonShot 2020 program. “We are honored to be a part of this momentous initiative,” said Michael Woods, president and CEO of Schulman IRB. “Schulman’s IRB members and staff are excited to partner with leaders in the oncology field in these landmark studies, and we... […]
IBM announced plans to launch its first Watson Health European Center of Excellence in Milan near the Human Technopole Italy 2040 research campus, supporting the government of Italy’s initiative to establish an international hub for the advancement of genomics, big data, aging, and nutrition. The center is part of a long-term collaboration between IBM and... […]
RARECYTE Inc. signed a Cooperative Research and Development Agreement with NCI for a three-year collaboration to investigate the use of RareCyte’s technology to identify, characterize, capture and analyze rare immune cell populations as well as individual circulating tumor cells derived from preclinical and clinical studies conducted by the NCI. The specific goals of the CRADA... […]
DANA-FARBER CANCER INSTITUTE and the ONTARIO INSTITUTE FOR CANCER RESEARCH joined the OHSU Knight Cancer Institute and Intel Corporation‘s Collaborative Cancer Cloud system, a distributed precision medicine analytics platform. The Collaborative Cancer Cloud works to determine how genes interact to drive disease in individual patients. The system is designed for secure, aggregated computation across distributed... […]
PAUL BUSHDID joined Southern Research to lead its Developmental & Reproductive Toxicology program. Previously, Bushdid spent 13 years at GlaxoSmithKline, where he headed an Investigative Developmental Toxicology group, where his work focused on agents that can cause birth defects or halt pregnancies. Bushdid’s team was also involved in DART assessments of traditional Chinese medicines, study... […]
TIMOTHY EBERLEIN was elected chairman of the board of directors of the National Comprehensive Cancer Network.
